Skip to main content

Table 1 Demographic and clinical characteristics of BU+HIV+ co-infected patients

From: Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana

Parameters

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Sex

Male

Male

Male

Male

Female

Female

Female

Female

Female

Age (years)

43

42

45

48

50

38

27

40

18

Lesion form

Ulcer

Ulcer

Ulcer

Ulcer

Ulcer

Ulcer

Ulcer

Nodule

Ulcer

Number of lesions

1

2

1

1

1

1

1

1

1

Category of lesion(s)

II

III

II

I

II

II

I

I

II

Lesion site

Upper limb

Lower limb

Lower limb

Lower limb

Back

Lower limb

Lower limb

Lower limb

Upper limb

Lesion healing week

16

52

LF

12

36

20

12

4

4

Occurrence of Paradoxical reaction (PR)

No

No

No PR

No PR

No PR

Yes (at week16)

No PR

No PR

No PR

Type of PR

NA

NA

NA

NA

NA

EWP

NA

NA

NA

HIV load (copies/mL)

 Baseline

224,856

134

I

255,950

17,538

76,448

ND

ND

ND

 After BU treatment

1988

LF

LF

1,318,694

140

25,272

60

2,576,972

13,227

CD4 count

 Baseline

         

 After BU treatment

130.02

   

750.3

815.04

753.532

80.6

 

Haemoglobin (g/dL)

 Baseline

11.7

11

10.3

10.3

9.8

9.8

11.8

8.7

9.7

 After treatment

12.5

LF

LF

9.3

9.8

9.1

10.7

5.61

ND

Weight (Kg)

 Baseline

63

56

50

42

45

66

44

49

52

 After treatment

62

60

55

44

49

67

46

43

60

Hepatitis B virus

–

–

+

–

–

–

–

–

–

Hepatitis C virus

–

–

–

–

–

–

–

+

–

Buruli ulcer regimen

RS

CR

RS

RS

RS

CR

RS

RS

RS

HIV treatment

3TC, d4T, EFV

not known

not known

not known

3TC, TDF, NVP

3TC, TDF, NVP

AZT, 3TC, NVP

AZT, 3TC, EFV

Not known

Patient on ART before initiation of BU treatment

No

NA

NA

NA

No

Yes

No

Yes

NA

  1. Abbreviations: − Negative, + Positive, RS Rifampicin and Streptomycin, CR Rifampicin and Clarithromycin, LF Lost to follow-up, I Invalid result, ND Not done, d4T Stavudine, 3TC Lamivudine, NVP Nevirapine, TDF Tenofovir, AZT Zidovudine, EFV Efavirenz, PR Paradoxical reaction, NA Not applicable, EWP Enlarged, warm to touch lesion